Orchid Pharma Limited (NSE: ORCHPHARMA)
1,490.85
+31.75 (2.18%)
Sep 6, 2024, 3:30 PM IST
Orchid Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
Revenue | 8,809 | 8,194 | 6,659 | 5,596 | 4,501 | 4,838 | Upgrade
|
Revenue Growth (YoY) | 22.71% | 23.05% | 19.00% | 24.33% | -6.97% | -19.36% | Upgrade
|
Cost of Revenue | 5,414 | 5,032 | 4,013 | 3,271 | 2,413 | 2,240 | Upgrade
|
Gross Profit | 3,395 | 3,162 | 2,646 | 2,325 | 2,088 | 2,598 | Upgrade
|
Selling, General & Admin | 787.64 | 729.83 | 663.66 | 648.58 | 686.14 | 863.42 | Upgrade
|
Other Operating Expenses | 1,395 | 1,323 | 1,145 | 1,145 | 817.22 | 1,277 | Upgrade
|
Operating Expenses | 2,522 | 2,386 | 2,357 | 2,664 | 2,593 | 3,320 | Upgrade
|
Operating Income | 872.39 | 776.25 | 289.93 | -338.9 | -504.94 | -721.75 | Upgrade
|
Interest Expense | -143.08 | -163.55 | -322.26 | -320.12 | -513.36 | -41.59 | Upgrade
|
Interest & Investment Income | 163.48 | 163.48 | 6.18 | 4.19 | 7.33 | 241.75 | Upgrade
|
Earnings From Equity Investments | -4.51 | -28.98 | -21.54 | -35.23 | - | - | Upgrade
|
Currency Exchange Gain (Loss) | 67.35 | 67.35 | 52.01 | 75.82 | 34.91 | -170.4 | Upgrade
|
Other Non Operating Income (Expenses) | 134.65 | 77.8 | 126.6 | 4.9 | 4.81 | -5.82 | Upgrade
|
EBT Excluding Unusual Items | 1,090 | 892.36 | 130.93 | -609.34 | -971.26 | -697.8 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | 0.15 | 5.12 | 19.42 | - | Upgrade
|
Gain (Loss) on Sale of Assets | -1.88 | -1.88 | 7.75 | 0 | -0.65 | 0.88 | Upgrade
|
Other Unusual Items | - | - | 392.1 | - | - | - | Upgrade
|
Pretax Income | 1,088 | 890.47 | 530.93 | -604.21 | -952.49 | -696.92 | Upgrade
|
Income Tax Expense | -32.73 | -31.19 | - | - | - | - | Upgrade
|
Earnings From Continuing Operations | 1,121 | 921.67 | 530.93 | -604.21 | -952.49 | -696.92 | Upgrade
|
Earnings From Discontinued Operations | - | - | -67.75 | 584.7 | -212.81 | -613.78 | Upgrade
|
Net Income to Company | 1,121 | 921.67 | 463.18 | -19.51 | -1,165 | -1,311 | Upgrade
|
Net Income | 1,121 | 921.67 | 463.18 | -19.51 | -1,165 | -1,311 | Upgrade
|
Net Income to Common | 1,121 | 921.67 | 463.18 | -19.51 | -1,165 | -1,311 | Upgrade
|
Net Income Growth | 58.49% | 98.99% | - | - | - | - | Upgrade
|
Shares Outstanding (Basic) | 48 | 48 | 41 | 41 | 41 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 48 | 48 | 41 | 41 | 41 | 0 | Upgrade
|
Shares Change (YoY) | 11.55% | 18.49% | - | - | 9914.82% | -0.15% | Upgrade
|
EPS (Basic) | 23.20 | 19.06 | 11.35 | -0.48 | -28.55 | -3215.97 | Upgrade
|
EPS (Diluted) | 23.20 | 19.06 | 11.35 | -0.48 | -28.55 | -3215.97 | Upgrade
|
EPS Growth | 42.09% | 67.93% | - | - | - | - | Upgrade
|
Free Cash Flow | - | 611.77 | -665.75 | 780.71 | 229.82 | 765.61 | Upgrade
|
Free Cash Flow Per Share | - | 12.65 | -16.31 | 19.13 | 5.63 | 1878.51 | Upgrade
|
Gross Margin | 38.54% | 38.59% | 39.74% | 41.54% | 46.38% | 53.70% | Upgrade
|
Operating Margin | 9.90% | 9.47% | 4.35% | -6.06% | -11.22% | -14.92% | Upgrade
|
Profit Margin | 12.73% | 11.25% | 6.96% | -0.35% | -25.89% | -27.09% | Upgrade
|
Free Cash Flow Margin | - | 7.47% | -10.00% | 13.95% | 5.11% | 15.82% | Upgrade
|
EBITDA | 1,133 | 1,094 | 837.72 | 531.03 | 583.9 | 457.25 | Upgrade
|
EBITDA Margin | 12.86% | 13.35% | 12.58% | 9.49% | 12.97% | 9.45% | Upgrade
|
D&A For EBITDA | 260.2 | 317.72 | 547.79 | 869.93 | 1,089 | 1,179 | Upgrade
|
EBIT | 872.39 | 776.25 | 289.93 | -338.9 | -504.94 | -721.75 | Upgrade
|
EBIT Margin | 9.90% | 9.47% | 4.35% | -6.06% | -11.22% | -14.92% | Upgrade
|
Revenue as Reported | 9,174 | 8,502 | 6,853 | 5,686 | 4,653 | 5,081 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.